Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoid

Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoid

Item

http://www.wikidata.org/entity/Q33607442

Q33607442

about

Production of glycoprotein vaccines in Escherichia coli Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1 Dipstick test for rapid diagnosis of Shigella dysenteriae 1 in bacterial cultures and its potential use on stool samples A multicentre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology Preparation, characterization, and immunogenicity in mice of a recombinant influenza H5 hemagglutinin vaccine against the avian H5N1 A/Vietnam/1203/2004 influenza virus A bicomponent Plasmodium falciparum investigational vaccine composed of protein-peptide conjugates.Comparison of O-antigen gene clusters of Escherichia coli (Shigella) sonnei and Plesiomonas shigelloides O17: sonnei gained its current plasmid-borne O-antigen genes from P. shigelloides in a recent event.Oligosaccharide conjugates of Bordetella pertussis and bronchiseptica induce bactericidal antibodies, an addition to pertussis vaccine.Immunochemical studies of Shigella flexneri 2a and 6, and Shigella dysenteriae type 1 O-specific polysaccharide-core fragments and their protein conjugates as vaccine candidates.Treatment with succinic anhydride improves the immunogenicity of Shigella flexneri type 2a O-specific polysaccharide-protein conjugates in mice Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel.Preparation, characterization, and immunological properties in mice of Escherichia coli O157 O-specific polysaccharide-protein conjugate vaccines Prevention and self-treatment of traveler's diarrhea.Poly(gamma-D-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: a potential addition to the anthrax vaccine.Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination.Protection against local Shigella sonnei infection in mice by parenteral immunization with a nucleoprotein subcellular vaccine Comparative immunogenicity of conjugates composed of Escherichia coli O111 O-specific polysaccharide, prepared by treatment with acetic acid or hydrazine, bound to tetanus toxoid by two synthetic schemes.Development of Shigella sonnei live oral vaccines based on defined rfbInaba deletion mutants of Vibrio cholerae expressing the Shigella serotype D O polysaccharide.Synthesis, characterization, and immunological properties in mice of conjugates composed of detoxified lipopolysaccharide of Salmonella paratyphi A bound to tetanus toxoid with emphasis on the role of O acetyls Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers.Construction and characterization of a live attenuated vaccine candidate against Shigella dysenteriae type 1.Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25.Live attenuated Shigella dysenteriae type 1 vaccine strains overexpressing shiga toxin B subunit.Comparison of conjugates composed of lipopolysaccharide from Shigella flexneri type 2a detoxified by two methods and bound to tetanus toxoid.O-Acetylation in the O-specific polysaccharide isolated from Shigella flexneri serotype 2a O-specific [corrected] polysaccharide conjugate vaccine-induced [corrected] antibodies prevent invasion of Shigella into Caco-2 cells and may be curative.Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni.Effect of the nonreducing end of Shigella dysenteriae type 1 O-specific oligosaccharides on their immunogenicity as conjugates in mice.O:2-CRM(197) conjugates against Salmonella Paratyphi A.Saccharide/protein conjugate vaccines for Bordetella species: preparation of saccharide, development of new conjugation procedures, and physico-chemical and immunological characterization of the conjugates.The elucidation of the structure of the core part of the LPS from Plesiomonas shigelloides serotype O17 expressing O-polysaccharide chain identical to the Shigella sonnei O-chain Progress and pitfalls in Shigella vaccine research.Monoclonal Antibodies to Shigella Lipopolysaccharide Are Useful for Vaccine Production.Synthesis, characterization, and immunogenicity in mice of Shigella sonnei O-specific oligosaccharide-core-protein conjugates Shigella Vaccine Development: Finding the Path of Least Resistance.The structural diversity of carbohydrate antigens of selected gram-negative marine bacteria.A scalable method for O-antigen purification applied to various Salmonella serovars.Construction, characterization, and animal testing of WRSd1, a Shigella dysenteriae 1 vaccine.Intransal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection.

P2860

Q24628546-FF867B64-B4C0-4B9F-85D8-460B1260B810 Q28343287-454963C7-C025-4B9B-87EF-20EE1CF8693A Q28744352-E3B2DBC7-23D3-4866-B327-5A9A0D73AA62 Q28767862-BAF0D757-BC62-4391-9E90-4A3480FA4641 Q30379914-72ED66F4-EE53-494C-A702-417A2D24FAD4 Q33524699-F0034F99-A637-4EA2-9DFD-B10C77741B6C Q33593386-0FC0658D-CEAD-4EAA-A318-B3D9E54026A9 Q33835015-08CC4807-8F74-461E-96AB-AFCE8B2DD09A Q33987735-338B9225-6BB0-4A5D-AB7D-5F571EECEF41 Q34002272-20BDC9B0-F934-418D-AD7A-A420599906DD Q34006223-D28D5CBF-740E-47DB-995D-A42C7A852522 Q34545082-59D88AEE-CCDA-4CF1-AFD5-EE5FBD35AC32 Q34974972-F6CF6296-5037-4524-804F-03D29F110381 Q35171265-DFB26C8E-70B9-4C06-AA57-3980274FB1E5 Q35227169-B45BD285-54CB-4FB5-AA35-C5E7126C0FCD Q35424942-AE7523B9-23DF-4734-AE25-4820BA1E7B04 Q35425792-0C9F8F6A-2965-43D4-B912-C1873E22F8A5 Q35469131-F08512AC-07AE-4E40-8650-BE04BF36BC6C Q35505761-FACA3CA9-0AD3-4E95-8F02-09FB15694455 Q35523144-C5961D65-2162-468A-B6DB-ACC14EB5B131 Q35548702-B34F26CD-F5C6-45A3-AC8C-FA499C07836F Q35575993-6566C783-7DB0-45A2-AA29-11737F1FAD4C Q35598035-69A69ECF-C0A3-4C43-813E-11AF4C8B5A7C Q35771562-4EC59BDB-EC70-495F-BF57-7124C9B693D1 Q35828313-73E1EE9F-AFD2-4F4D-9F70-77979B0FD5F5 Q35844488-7372B25E-F87C-455E-8681-4D0E8109459F Q35887055-C6A2ECC2-C5C1-4D2D-9828-E4FF144B99D5 Q35955978-4667B065-DC7D-48EA-927C-C3C71223276D Q36380921-6480AD73-2374-44EC-BAAA-E638A2D2FC52 Q36842967-52995065-0CFF-433D-96B9-2E3B1A1D1DA1 Q36993963-435D9DDE-F64B-4230-9835-DE76F167A4E1 Q37105553-B67C47E3-A075-41C6-A444-A459481C19D5 Q37163698-C35862C1-C1EA-4E68-981E-72CF1317DB65 Q37194696-26567D9E-DD15-4EA7-AFEF-816FA9B121C6 Q37477191-1927FA6C-526B-4A00-A243-9D5C77596ED6 Q37954615-B93C4119-2819-457A-AB07-35F029838681 Q38538720-9606D3AC-6BF8-4E44-9E85-705DED0761E4 Q39655324-3D9B99E0-D229-42BF-B3CF-B18ECF3B9495 Q39822312-3B45A165-62BF-4648-B965-0D4146E0C55C

P2860

Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoid

Item

http://www.wikidata.org/entity/Q33607442

description

1993 nî lūn-bûn

@nan

1993 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

1993 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

1993年の論文

@ja

1993年論文

@yue

1993年論文

@zh-hant

1993年論文

@zh-hk

1993年論文

@zh-mo

1993年論文

@zh-tw

1993年论文

@wuu